Recombinant human CD48 protein (C-6*HIS)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

C-6*HIS

Activity

EC50: 10-41 ng/mL

Cat no : Eg1005



Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Immobilized Human CD48 (His tag) at 2 μg/mL (100 μL/well) can bind Human CD244 (rFc tag) with a linear range of 10-41 ng/mL.
Expression HEK293-derived Human CD48 protein Gln27-Ser220 (Accession# P09326) with a His tag at the C-terminus.
GeneID 962
Accession P09326
PredictedSize 21.7 kDa
SDS-PAGE
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Signaling lymphocytic activation molecule family 2 (SLAMF2, CD48) is an adhesion and costimulatory molecule expressed constitutively on most hematopoietic cells, particularly in antigen presenting cells (APC). CD48 is expressed on all the hematopoietic cells, both in human and mice, except for murine neutrophils and long term-HSC. as a number of GpI receptors do, also CD48 exists as both a membrane bound (mCD48) and a soluble (sCD48) form. CD48 can have activating roles on T cells, antigen presenting cells and granulocytes, by binding to CD2 or bacterial FimH, and through cell intrinsic effects. Interactions between CD48 and its high affinity ligand CD244 are more complex, with both stimulatory and inhibitory outcomes. CD48 expression is increased in autoimmunity and allergy diseases, and anti-CD48 monoclonal antibodies have been shown to attenuate experimental autoimmune encephalomyelitis.

References:

1.Cunyi Zou. et al. (2019). Onco Targets Ther. 12:4181-4193. 2.Shannon L McArdel. et al. (2016). Clin Immunol. 164:10-20. 3.Hadas Pahima. et al. (2019). Clin Immunol. 204:64-68. 4.Shannon L McArdel. et al. (2016). J Immunol. 197(8):3038-3048.